Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trialResearch in context

• Egile Nagusiak: Israel S. Maia (Egilea), Aline Marcadenti (Egilea), Viviane C. Veiga (Egilea), Tamiris A. Miranda (Egilea), Samara P.C. Gomes (Egilea), Mariana B.S. Carollo (Egilea), Karina L. Negrelli (Egilea), Jackeline O. Gomes (Egilea), Lucas Tramujas (Egilea), Erlon O. Abreu-Silva (Egilea), Glauco A. Westphal (Egilea), Ruthy P. Fernandes (Egilea), Jacques G.A. Horta (Egilea), Deborah C. Oliveira (Egilea), Uri A.P. Flato (Egilea), Ricardo C.R. Paoliello (Egilea), Camilo Fernandes (Egilea), Cássio L. Zandonai (Egilea), Juliana C. Coelho (Egilea), Waldemar C. Barros (Egilea), Juliana C. Lemos (Egilea), Renata S. Bolan (Egilea), Marcela M. Dutra (Egilea), Otavio C.E. Gebara (Egilea), Ana T.A. Lopes (Egilea), Meton S. Alencar Filho (Egilea), Jussara A. Arraes (Egilea), Victor A. Hamamoto (Egilea), Mauro E. Hernandes (Egilea), Nicole A. Golin (Egilea), Tiago M. Santos (Egilea), Renato H.N. Santos (Egilea), Lucas P. Damiani (Egilea), Fernando G. Zampieri (Egilea), João Gesto (Egilea), Flávia R. Machado (Egilea), Régis G. Rosa (Egilea), Luciano C.P. Azevedo (Egilea), Alvaro Avezum (Egilea), Renato D. Lopes (Egilea), Thiago M.L. Souza (Egilea), Otávio Berwanger (Egilea), Alexandre B. Cavalcanti (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients. Methods: REVOLUTIOn is a randomised, parallel, blin...